Current status and future directions in the pharmacotherapy of epilepsy - PubMed (original) (raw)
Review
Current status and future directions in the pharmacotherapy of epilepsy
Wolfgang Löscher. Trends Pharmacol Sci. 2002 Mar.
Abstract
Considerable progress in the pharmacotherapy of epilepsy has been witnessed during the 20th century. However, despite the development of various antiepileptic drugs, about a third of patients are resistant to current pharmacotherapies. Even in patients in whom pharmacotherapy is efficacious, current antiepileptic drugs do not affect the progression or underlying natural history of the condition. Furthermore, currently there are no drugs available that prevent the development of epilepsy following, for example, head trauma. The rapid expansion of information about the cellular, molecular and genetic mechanisms of epilepsy is expected to lead to more effective therapies, prevention or even a cure for different types of epilepsy. In this article, I assess the current status of antiepileptic therapies and highlight innovative approaches for future treatments.
Similar articles
- [The new antiepileptic drugs: their indications and side effects].
Malagón-Valdez J. Malagón-Valdez J. Rev Neurol. 2004 Sep 16-30;39(6):570-5. Rev Neurol. 2004. PMID: 15467997 Review. Spanish. - New horizons in the development of antiepileptic drugs.
Löscher W, Schmidt D. Löscher W, et al. Epilepsy Res. 2002 Jun;50(1-2):3-16. doi: 10.1016/s0920-1211(02)00063-3. Epilepsy Res. 2002. PMID: 12151112 Review. - New horizons in the development of antiepileptic drugs: the search for new targets.
Löscher W, Schmidt D. Löscher W, et al. Epilepsy Res. 2004 Jul-Aug;60(2-3):77-159. doi: 10.1016/j.eplepsyres.2004.06.004. Epilepsy Res. 2004. PMID: 15540387 - Multidrug resistance 1 (MDR1) gene polymorphisms in childhood drug-resistant epilepsy.
Alpman A, Ozkinay F, Tekgul H, Gokben S, Pehlivan S, Schalling M, Ozkinay C. Alpman A, et al. J Child Neurol. 2010 Dec;25(12):1485-90. doi: 10.1177/0883073810368997. Epub 2010 May 6. J Child Neurol. 2010. PMID: 20448249 - Signaling to P-glycoprotein-A new therapeutic target to treat drug-resistant epilepsy?
Hartz AM, Notenboom S, Bauer B. Hartz AM, et al. Drug News Perspect. 2009 Sep;22(7):393-7. doi: 10.1358/dnp.2009.22.7.1401354. Drug News Perspect. 2009. PMID: 19890496 Review.
Cited by
- Clinical characteristics of patients with benign nonlesional temporal lobe epilepsy.
Kim J, Kim SH, Lim SC, Kim W, Shon YM. Kim J, et al. Neuropsychiatr Dis Treat. 2016 Jul 28;12:1887-91. doi: 10.2147/NDT.S110400. eCollection 2016. Neuropsychiatr Dis Treat. 2016. PMID: 27555776 Free PMC article. - Novel actions of oxazolidinones: in vitro screening of a triazolyloxazolidinone for anticonvulsant activity.
Kombian SB, Phillips OA. Kombian SB, et al. Med Princ Pract. 2013;22(4):340-5. doi: 10.1159/000346005. Epub 2012 Dec 21. Med Princ Pract. 2013. PMID: 23257573 Free PMC article. - Mechanisms of seizure propagation in 2-dimensional centre-surround recurrent networks.
Hall D, Kuhlmann L. Hall D, et al. PLoS One. 2013 Aug 13;8(8):e71369. doi: 10.1371/journal.pone.0071369. eCollection 2013. PLoS One. 2013. PMID: 23967201 Free PMC article. - Anticonvulsant and related neuropharmacological effects of the whole plant extract of Synedrella nodiflora (L.) Gaertn (Asteraceae).
Amoateng P, Woode E, Kombian SB. Amoateng P, et al. J Pharm Bioallied Sci. 2012 Apr;4(2):140-8. doi: 10.4103/0975-7406.94816. J Pharm Bioallied Sci. 2012. PMID: 22557925 Free PMC article. - Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.
Barker-Haliski M, Steve White H. Barker-Haliski M, et al. Neuropharmacology. 2020 May 1;167:107750. doi: 10.1016/j.neuropharm.2019.107750. Epub 2019 Aug 27. Neuropharmacology. 2020. PMID: 31469995 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical